GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Bioorganic & Medicinal Chemistry, Elsevier BV, Vol. 23, No. 9 ( 2015-05), p. 2241-2246
    Type of Medium: Online Resource
    ISSN: 0968-0896
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2015
    detail.hit.zdb_id: 1501507-5
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Spandidos Publications ; 2014
    In:  International Journal of Oncology Vol. 44, No. 4 ( 2014-04), p. 1131-1138
    In: International Journal of Oncology, Spandidos Publications, Vol. 44, No. 4 ( 2014-04), p. 1131-1138
    Type of Medium: Online Resource
    ISSN: 1019-6439 , 1791-2423
    RVK:
    Language: English
    Publisher: Spandidos Publications
    Publication Date: 2014
    detail.hit.zdb_id: 2079608-0
    detail.hit.zdb_id: 1154403-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical and Experimental Hematopathology, Japanese Society for Lymphoreticular Tissue Research, Vol. 54, No. 2 ( 2014), p. 137-141
    Type of Medium: Online Resource
    ISSN: 1346-4280 , 1880-9952
    Language: English
    Publisher: Japanese Society for Lymphoreticular Tissue Research
    Publication Date: 2014
    detail.hit.zdb_id: 2395568-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 2954-2954
    Abstract: Abstract 2954 Introduction: The first-in-class proteasome inhibitor bortezomib (Bzb) has revolutionized the treatment of multiple myeloma (MM). However, identifying a biomarker to predict which patients will respond to Bzb is a priority in selecting this treatment or determining whether this powerful but toxic armament should be continued in individual patients. Furthermore, to monitor the efficacy of Bzb, peripheral blood (PB) biomarkers are more desirable than painful bone marrow aspirations. Methods: We conducted a multicenter prospective study to seek biomarkers that predict a response to Bzb. Patients with previously treated or untreated symptomatic MM received twice-weekly or weekly doses of 1.3 mg/m2 Bzb with or without dexamethasone. All patients had measurable M-protein levels. All patients provided written informed consent. Review boards at each site approved the study, which was conducted in accordance with the Declaration of Helsinki. A 2 ml sample of heparinized whole blood was obtained before treatment, as well as 2–3 days and 1–2 weeks after i.v. administration of the first dose of Bzb treatment in the 1st cycle. Triplicate aliquots of 0.06 ml of whole blood were mixed with phytohemaglutinin (PHA), heat-aggregated IgG (HAG), lipopolysaccharide (LPS), zymosan A (ZA), or solvent phosphate buffered saline (PBS) and incubated for 4 hours at 37°C. After incubation, the samples were stored at −80°C. The levels of the target mRNAs (IL2, IFNγ, GMCSF, TNFα, CCL4, IL6, CXCL10, and control ACTB) were quantified from each aliquot using a previously described method (J Immunol Methods 363: 95, 2010). The analysis of mRNA and collection of clinical data were performed separately at different centers. Clinical response was assessed according to the International Uniform Response Criteria. Results: Between March 2010 and March 2012, a total of 64 patients (33 male and 31 female) were enrolled from 6 centers. The median age of all patients was 62 years. The original protocol stipulated that only relapsed or refractory patients were eligible, but in October 2011, the protocol was amended to include newly diagnosed patients due to changes in the Japanese National Health Insurance policy. Consequently, 42 patients were previously treated and 22 patients were untreated. After excluding 1 patient who died early from progressive disease and 1 who received additional treatment, 62 patients were eligible for response analysis. Five patients achieved CR and VGPR, 25 patients obtained PR and SD, and 2 cases of PD were documented. The median follow-up time of estimable patients was 160.5 (range, 26 to 666) days. A total of 2,444 (64 [patients] × 5 [stimulants] × 3 [triplicate] × 3 [time points] with some sampling failure subtracted) mRNA/cDNA samples were prepared, and 19,552 (2,444 [cDNA] × 8 [mRNAs]) PCRs were performed. In total, 53 patient blood samples qualified for mRNA analysis. Among the 32 sample dataset (4 stimulants × 8 mRNAs) obtained before Bzb treatment, LPS-induced CXCL10 correlated with clinical responses, where 9 out of 10 cases of CR and VGPR showed a 〉 =3 fold increase (FI), and both cases of PD showed an FI 〈 3. The FI of PR and SD was distributed widely without a clear distinction. Moreover, after administration of Bzb, LPS-induced CXCL10 declined to less than 30% in all cases of CR and VGPR, whereas PR and SD had mixed results. Interestingly, 7 out of 10 CR and VGPR cases maintained the suppression of LPS-induced CXCL10, even after 1–2 weeks. Conclusion: LPS-induced CXCL10 mRNA in peripheral whole blood is a promising biomarker for the prediction and monitoring of CR and VGPR responses to Bzb treatment. Disclosures: Mitsuhashi: the company who owns the technology of mRNA analysis used in this study: Employment. Abe:Janssen Pharmaceutical K.K.: Honoraria, Research Funding. Nakagawa:Janssen Pharmaceutical K.K.: Honoraria. Nakamura:Janssen Pharmaceutical K.K.: Honoraria. Iida:Janssen Pharmaceutical K.K.: Honoraria. Kizaki:Janssen Pharmaceutical K.K.: Honoraria.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    American Society of Hematology ; 2006
    In:  Blood Vol. 108, No. 11 ( 2006-11-16), p. 1923-1923
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 1923-1923
    Abstract: The therapeutic approach to acute myelogenous leukemia (AML) is usually chemotherapy, but severe side effects and complications, including infection and bleeding induced by the anticancer drugs, are major problems in the clinical setting. Recently, more specifically targeted agents have been developed for the treatment of AML; however, most candidate agents for targeted therapy have yet to be translated into clinical application. In the future, it will be important to identify other highly specific therapeutic agents based on our evolving understanding of the biology of AML. We have reported that reactive oxygen species (ROS) are key mediators of apoptosis induced by a green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), and other ROS-producing agents, in myeloid leukemic cells (Haematologica2005;90:317–325). In this study, we further examined the mechanism of oxidative stress-induced apoptosis and its relationship to the heme enzyme myeloperoxidase (MPO). EGCG rapidly induced apoptosis in MPO-positive (HL-60, UF-1, NB4, Kasumi-1), but not MPO-negative (U937, THP-1, KG-1, K562) leukemia cell lines as well as fresh samples from AML. Pre-incubation of MPO-positive leukemic cells with the MPO-specific inhibitor, 4-aminobenzoic acid hydrazide, and the heme biosynthesis inhibitor, succinylacetone, resulted in inhibition of the intracellular MPO activity, ROS production and induction of apoptosis following addition of EGCG. To investigate the role of MPO in EGCG-induced apoptosis, we transfected the full length MPO cDNA and empty vector into MPO-negative K562 cells (designated K562/MPO and K562/Cont cells, respectively). In contrast to K562/Cont cells, K562/MPO cells enhanced MPO activity and ROS production, and sensitized EGCG-resistant K562 cells to apoptosis induced by ROS-producing agents. In addition, an enzymatically inactive MPO mutant expressing K562 (K562/H502A) cells could not respond to EGCG, suggesting that MPO is important for determining the sensitivity to EGCG-induced oxidative stress. MPO catalyzes the formation of HOCl, a powerful oxidant formed from chloride ions and H2O2. We next examined the relationship between EGCG-induced apoptosis and the H2O2/MPO/halide system in MPO-positive myeloid leukemic cells. Further examination revealed that both HOCl scavengers (methionine, taurine) and the hydroxyl radical (·OH) scavenger thiourea inhibited EGCG-induced apoptosis in myeloid leukemic cells. To determine which ROS play a key role in oxidative stress-induced apoptosis mediated through MPO, we used the novel fluorescence probes AFP and HPF to detect highly toxic ROS (·OH). It is noteworthy that the fluorescence intensity of both APF- and HPF-loaded myeloid leukemic cells significantly increased upon stimulation with EGCG, suggesting that EGCG generated highly toxic ROS (·OH) in MPO-positive leukemic cells. Interestingly, the combination of EGCG and other ROS-producing agents (As2O3, doxorubicin, and daunorubicin) enhanced apoptosis through an increase in the production of highly toxic ROS in myeloid leukemic cells. Taken together, these observations indicate that highly toxic ROS (·OH) generated via the H2O2/MPO/halide system induce apoptosis, and that such ROS may be the direct mediators of oxidative stress-induced apoptosis in MPO-positive leukemic cells. “MPO-targeted therapy” will lead to new insights that should help in overcoming drug resistance in refractory AML.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-01), p. 2097-2097
    Abstract: CD47 belongs to the immunoglobulin superfamily, and is expressed as a 50 kDa cell surface antigen in a wide variety of tissues. CD47 is associated with integrins of β1, β2, and β3, and serves as both a receptor for thrombospondin (TSP) and a ligand for the transmembrane signal regulatory protein SIRP-α . CD47 has a number of different functions, including platelet activation, cell motility, leukocyte adhesion, migration and phagocytosis. Recently, it was reported that the ligation of CD47 rapidly induces cell death in T-cells and chronic lymphocytic leukemic B cells (B-CLL) in a caspase-independent manner (Nat Med, 1999;5:1277–1284). These findings indicate that CD47 ligation may have potential as a new therapeutic approach for lymphoid malignancies. B-CLL is the most common hematological malignancy in Western countries. Although new therapeutic agents such as fludarabine and 2-chlorodeoxyadenosine have been introduced in the clinic, B-CLL is not considered curable, and thus there is an immediate need for new, effective drugs. In an attempt to establish a novel therapeutic agent for B-CLL, we first generated a murine monoclonal antibody against an extracellular domain of human CD47 (designated MABL). Soluble MABL (10μg/ml) with goat anti-mouse IgG (GAM) induced apoptosis of CD47-positive CCRF-CEM and MOLT-4 cells. However, because MABL caused hemoagglutination, we created a disulfide-stabilized dimer of a single-chain antibody fragment of MABL (S-S diabody) to get rid of this adverse effect. The S-S diabody did not cause hemoagglutination. Treatment with the S-S diabody (0–0.1 μg/ml for 0–24 hours) alone was fully active in inducing apoptosis of primary samples from patients with B-CLL and CD47-positive lymphoid cells (MOLT-4 and JOK-1) in a dose- and time-dependent manner. In addition, administration of the S-S diabody (30 mg/kg for 5 days) significantly prolonged the survival of SCID mice inoculated with JOK-1 cells compared with that of the control mice (median survival 21 days vs. more than 30 days, p 〈 0.05). These results demonstrate that the S-S diabody induced the ligation of CD47 more efficiently than original MABL without causing hemoagglutination. Transmission electron microscopic analysis showed that the S-S diabody induced typical morphological changes of apoptosis as well as cell-cell adhesion in MOLT-4 cells. To address the molecular mechanism of apoptosis by the ligation of CD47 with the S-S diabody, we performed gene expression profiling analysis. Gene expression profiling with Affimetrix gene chips of MOLT-4 cells demonstrated 54 genes, including HIF-1a and its down-stream genes (RTP801, EGR-1, BNIP3, and VEGF), that were upregulated by the treatment with S-S diabody. Moreover, knockdown of these molecules by siRNA partially repressed S-S diabody-induced apoptosis in MOLT-4 cells. These results suggest that induction of apoptosis by CD47 ligation may be mediated through various HIF-1α pathways. In conclusion, CD47 will be a molecular target for the treatment of lymphoid malignancies. In addition, the newly established disulfide-stabilized dimer of a single-chain antibody fragment of MABL (S-S diabody) may have potential as a novel therapeutic agent for the treatment of B-CLL and other incurable lymphoid malignancies.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 5758-5758
    Abstract: Background: Substantial efficacy has been demonstrated with bortezomib (Bor)-containing regimens for the treatment of refractory/relapsed (RR) patients with transplant-ineligible (TI) multiple myeloma (MM). However, the dosing schedules for induction therapy and the significance of maintenance therapy using Bor in clinical settings have yet to be standardized. Discontinuations and dose reduction of Bor owing to severe adverse events (AEs) such as peripheral neuropathy (PN) and infection are frequent causes of adjustments to the standard 9 cycles of Bor/dexamethasone (BD) therapy used for induction in clinical practice. We have previously demonstrated that a change in Bor administration to a schedule of weekly or longer intervals had similar or greater efficacy for patients with RR-MM including transplant-eligible (Tokuhira M, et al. Leuk Res. 35:591-7, 2011). To investigate the efficacy of this modified Bor dosing schedule in the treatment focusing of TI-RR-MM, we retrospectively analyzed 22 patients receiving weekly-BD induction followed by a modified schedule of biweekly or longer intervals using Bor as maintenance therapy in a single institution. Methods: Data on the 22 TI-RR-MM patients treated with BD therapy in our institution were retrospectively analyzed. The induction therapy consisted of intravenous injections of Bor (1.3 mg/m2) on days 1, 8, 15, and 22 in combination with dexamethasone (10–20 mg) on days 1 and 2 after Bor infusion, every 5 weeks. After BD induction, Bor maintenance was initiated with a schedule of biweekly or longer intervals. The dose of BD could be reduced based on AEs or other social aspects at the discretion of the treating physician. Overall survival (OS) was defined as the period between BD initiation of treatment to the last follow-up. Results: The median age of patients at the time of BD induction was 72.6 years (range, 49–84 years), and the subtypes of MM were the IgG type in 14 patients, IgA type in 6 patients, and BJP in 2 patients. Twelve patients were men and 10 were women. On the basis of the International Staging System classification, the clinical stage was I in 3 patients, II in 16 patients, and III in 3 patients. The median number of prior treatment regimens was 2.0 (range, 1–6). The median follow-up duration was 4.3 years (inter-quartile range, 3.0–7.8 years). Ten patients were alive, and 12 patients had died at the time of reporting. The median duration from the start of the first line treatment to BD initiation was 1.8 years (range, 0.1–14.8 years). The median number of BD induction cycles was 2.0 (range, 1–6), and 8 patients (36%) achieved a partial response (PR), although the other 14 patients (64%) showed stable disease or only a minimal response. Although AEs such as PN and gastrointestinal tract symptoms developed in 10 of 22 patients during BD induction, all 22 patients could move on to the maintenance phase. The median duration of Bor maintenance was 14.5 months (range, 1.8–76.5 months). Three patients were still receiving maintenance therapy at the time of reporting. Six patients (27.2%) received maintenance therapy for over 2 years, and 3 (13.6%) received it for over 4 years. The median OS was 3.6 years (range, 0.4–6.5 years), and the duration of Bor therapy from induction to the last administration was 2.5 years. The median progression free survival was 1.6 years (range, 0.3–6.5 years). During maintenance therapy, 5 patients achieved a PR. The reasons for cessation of Bor maintenance therapy were AEs in 8 patients and progressive disease in 11 patients. No patient died during Bor administration in this study. Discussion: We retrospectively analyzed 22 TI-RR-MM patients receiving modified BD therapy. Pantani L et al. reported the results of using BD therapy for 85 RR-MM patients, and demonstrated that twice-weekly Bor administration resulted in a clinical response rate of 19% and a median OS of 22 months (Ann Hematol, 2014). Although the clinical response rate in our study was inferior to that of Pantani L et al., the median OS in our study was superior (3.6 years) than those of previous reports. Because the majority of patients in this study were frail or elderly, the early decision to change to maintenance therapy before they developed severe AEs resulted in a good clinical outcome and a longer OS. Continuing BD therapy without a satisfactory molecular response might be an attractive therapeutic approach for TI-RR-MM patients. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 4429-4429
    Abstract: Green tea polyphenol, (−)-epigallocatechin-3-gallate (EGCG), has a potent chemopreventive effects against various tumors, and epidemiologic studies have suggested that green tea consumption might be effective for reducing the incidence of certain cancers. We have reported that EGCG rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species (ROS) production in vitro and in vivo (Haematologica2005;90:317). In this study, we further examined the precise mechanism of EGCG-induced apoptosis and its relationship to the heme enzyme myeloperoxidase (MPO). EGCG inhibited cellular growth of various myeloid leukemic cells via induction of apoptosis in dose- and time-dependent manners. Interestingly, EGCG rapidly induced apoptosis in MPO-positive myeloid leukemic cell lines (HL-60, UF-1, NB4, Kasumi-1) and fresh myeloid leukemic cells from patients, whereas EGCG failed to induce apoptosis in MPO-negative leukemic cells (U937, THP-1, KG-1, K562). Pre-incubation of MPO-positive myeloid leukemic cells with the MPO-specific inhibitor, 4-aminobenzoic acid hydrazide (50 μM), and the heme biosynthesis inhibitor, succinylacetone (0.5 mM), resulted in significant inhibition of intracellular MPO activity, ROS production, and induction of apoptosis after treatment with 50 μM EGCG. Pre-incubation of MPO-positive myeloid leukemic cells with anti-oxidant, catalase, completely suppressed EGCG-induced ROS production and apoptosis. These results indicate that EGCG-induced apoptosis is mediated through the generation of hydrogen peroxide (H2O2). To investigate the role of MPO in EGCG-induced apoptosis of leukemic cells, MPO-negative K562 cells were stably transfected with full length of MPO cDNA (K562/MPO cells). Marked interest, K562/MPO cells induced MPO activity, intracellular ROS production, and enhanced susceptibility of cells to EGCG-induced apoptosis compared to wild-type K562 cells. These results suggested that MPO positivity may be important to determine the sensitivity to EGCG-induced apoptosis, and MPO-derived ROS are involved in apoptosis in myeloid leukemic cells. MPO catalyzes the formation of hypochlorous acid (HOCl), a powerful oxidant formed from Cl− and H2O2. Therefore, we next examined the relationship between EGCG-induced apoptosis and H2O2/MPO/halide system in MPO-positive HL-60 cells. Addition of HOCl scavengers, methionine (10 mM) and taurine (25 mM), inhibited EGCG-induced apoptosis in HL-60 and K562/MPO cells, but not wild-type K562 cells, suggesting that HOCl is the mediator of EGCG-induced apoptosis. Interestingly, hydroxyl radical (•OH) scavenger, thiourea, also inhibited EGCG-induced apoptosis in HL-60 cells. To determine which reactive oxygen species play a key role in EGCG-induced apoptosis mediated through MPO, we used novel fluorescence probes APF and HPF, which can detect selectively highly ROS (hROS). It is noteworthy that the fluorescence intensity of both APF- and HPF-loaded HL-60 cells significantly increased upon stimulation with EGCG, suggesting that EGCG generated hROS (•OH, ONOO−) and OCl−, but not other ROS (H2O2, NO, O2−, 1O2) in HL-60 cells. Taken together, these results indicated that highly toxic ROS such as hydroxyl radical generated via H2O2/MPO/halide system induces apoptosis, and that it may be the direct mediator of EGCG-induced apoptosis in MPO-positive myeloid leukemic cells.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Annals of Oncology, Elsevier BV, Vol. 26 ( 2015-11), p. vii111-
    Type of Medium: Online Resource
    ISSN: 0923-7534
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2015
    detail.hit.zdb_id: 2003498-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...